Hospira Recalls Bupivacaine HCl Injection
The company voluntarily recalls Preservative-Free Bupivacaine HCl Injection, USP due to potential iron oxide particulates.
Hospira announced on April 23, 2015 it was voluntarily recalling one lot of Preservative-Free Bupivacaine hydrochloride (HCl) Injection, USP, 0.5% (5 mg/mL), 30 mL Single-dose (NDC: 0409-1162-02, Lot 38-515-DK, Expiry 1FEB2016). The recall comes after confirmed complaints from a customer of orange and black, visible particles found in a single-dose glass teartop vial. The recalled lot was distributed from July to September 2014.
Hospira has identified the particles as iron oxide and is investigating the root cause of the particulates. The company says it working with their glass supplier as part of the investigation.
Source: FDA.gov
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
